Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice

In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component c...

Full description

Saved in:
Bibliographic Details
Published inInternational immunopharmacology Vol. 55; pp. 306 - 311
Main Authors Dong, Bohan, Dai, Guangli, Ding, Yuanyuan, Wang, Beiru, Zhang, Siyuan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.02.2018
Elsevier BV
Subjects
Anti-tumor immunity
Antigens
Apoptosis
Cancer
Cancer vaccines
FasL
FasL protein
Immunity
Immunity (Disease)
Immunization
Interleukin 2
Lung cancer
Lung carcinoma
Mice
Mouse splenocytes
Splenocytes
Tumor cell lysate
Tumors
Vaccines
Tumor cell lysate
FasL
Mouse splenocytes
Lung cancer
Apoptosis
Anti-tumor immunity
Online AccessGet full text

Cover

Abstract In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component can be eliminated from TCL, the anti-tumor immunity of MHSP65-TCL constructed with TCL should be improved. In the present study, we knocked down FasL from Lewis lung carcinoma cells and prepared MHSP65-(FasL-/TCL) with this cell line's TCL. After further investigation, MHSP65-(FasL-/TCL) exhibited a better ability to reduce splenocytes apoptosis, promote its activation and secretion of secretingTNF-β, IL-2 compared with MHSP65-(FasL+/TCL). Accordingly, specific and nonspecific antitumor immunity induced by MHSP65-(FasL-/TCL) is stronger than that of MHSP65-(FasL+/TCL). In vivo, MHSP65-(FasL-/TCL) immunization can prolong survival of Lewis lung carcinoma bearing mice. Thus, we report that the anti-lung cancer effect of MHSP65-TCL can be improved by removal of FasL from the TCL. It provides a new route to construct MHSP65-TCL and other antitumor vaccines based on TCL. •Constructed a MHSP65-(FasL-/TCL) anti-lung cancer vaccine with the TCL removed FasL (FasL-/TCL).•MHSP65-(FasL-/TCL) can induce stronger nonspecific and specific anti-lung cancer immunity than MHSP65-(FasL+/TCL).•MHSP65-(FasL-/TCL) immunization can prolong survival of tumor bearing mice compared with that of MHSP65-(FasL+/TCL).•Theoretically, the method eliminated FasL from TCL can be applied in all the immunotherapy based on TCL.
AbstractList In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component can be eliminated from TCL, the anti-tumor immunity of MHSP65-TCL constructed with TCL should be improved. In the present study, we knocked down FasL from Lewis lung carcinoma cells and prepared MHSP65-(FasL-/TCL) with this cell line's TCL. After further investigation, MHSP65-(FasL-/TCL) exhibited a better ability to reduce splenocytes apoptosis, promote its activation and secretion of secretingTNF-β, IL-2 compared with MHSP65-(FasL+/TCL). Accordingly, specific and nonspecific antitumor immunity induced by MHSP65-(FasL-/TCL) is stronger than that of MHSP65-(FasL+/TCL). In vivo, MHSP65-(FasL-/TCL) immunization can prolong survival of Lewis lung carcinoma bearing mice. Thus, we report that the anti-lung cancer effect of MHSP65-TCL can be improved by removal of FasL from the TCL. It provides a new route to construct MHSP65-TCL and other antitumor vaccines based on TCL.
In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component can be eliminated from TCL, the anti-tumor immunity of MHSP65-TCL constructed with TCL should be improved. In the present study, we knocked down FasL from Lewis lung carcinoma cells and prepared MHSP65-(FasL-/TCL) with this cell line's TCL. After further investigation, MHSP65-(FasL-/TCL) exhibited a better ability to reduce splenocytes apoptosis, promote its activation and secretion of secretingTNF-β, IL-2 compared with MHSP65-(FasL+/TCL). Accordingly, specific and nonspecific antitumor immunity induced by MHSP65-(FasL-/TCL) is stronger than that of MHSP65-(FasL+/TCL). In vivo, MHSP65-(FasL-/TCL) immunization can prolong survival of Lewis lung carcinoma bearing mice. Thus, we report that the anti-lung cancer effect of MHSP65-TCL can be improved by removal of FasL from the TCL. It provides a new route to construct MHSP65-TCL and other antitumor vaccines based on TCL. •Constructed a MHSP65-(FasL-/TCL) anti-lung cancer vaccine with the TCL removed FasL (FasL-/TCL).•MHSP65-(FasL-/TCL) can induce stronger nonspecific and specific anti-lung cancer immunity than MHSP65-(FasL+/TCL).•MHSP65-(FasL-/TCL) immunization can prolong survival of tumor bearing mice compared with that of MHSP65-(FasL+/TCL).•Theoretically, the method eliminated FasL from TCL can be applied in all the immunotherapy based on TCL.
Author Ding, Yuanyuan
Dai, Guangli
Dong, Bohan
Wang, Beiru
Zhang, Siyuan
Author_xml – sequence: 1
  givenname: Bohan
  surname: Dong
  fullname: Dong, Bohan
  email: 240151563@qq.com, 20100044@wnmc.edu.cn
  organization: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, PR China
– sequence: 2
  givenname: Guangli
  surname: Dai
  fullname: Dai, Guangli
  organization: Department of Gynaecology and Obstetrics, Traditional Chinese Medical Hospital of Wuhu, Wuhu, Anhui 241000, PR China
– sequence: 3
  givenname: Yuanyuan
  surname: Ding
  fullname: Ding, Yuanyuan
  organization: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, PR China
– sequence: 4
  givenname: Beiru
  surname: Wang
  fullname: Wang, Beiru
  organization: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, PR China
– sequence: 5
  givenname: Siyuan
  surname: Zhang
  fullname: Zhang, Siyuan
  organization: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29310106$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtr3DAURkVJyKv5B6UIuunGzpVk-bEJlKF5wJQEkha6Ehr5utVgyxPJTsi_zx0mzSKLaiOBzv2-yzlme2EMyNgnAbkAUZ6tcx8mP2xyCaLKhcxBNh_YkairOhMV6D1667LKdFU2h-w4pTUQCIU4YIeyUZQB5RH7_cs654Od_Bj4k5_-8gubltnZ_WLJN_2c-I-ru9tScx_a2WHiVBjHR2y5pfKsn8Mf7mxwGOlnmIOfngnlg3f4ke13tk94-nqfsJ8X3-8XV9ny5vJ68W2ZOaWaKWtlYUW3csphhcKJrgMlpKyLWnVQ1Rawg1LVEjoFK91qtLpWlZZaWgetVuqEfd3l0mIPM6bJDD457HsbcJyTEU3daJJQSEK_vEPX4xwDbWcklNvTCCCq2FEujilF7Mwm-sHGZyPAbNWbtdmpN1v1RkhD6mns82v4vBqwfRv655qA8x2AZOPRYzTJeSR3rY_oJtOO_v8NL1hIloA
Cites_doi 10.3892/or.2017.5629
10.1074/jbc.M709000200
10.1182/blood-2009-01-200923
10.32607/20758251-2016-8-3-17-30
10.1089/cbr.2009.0716
10.3892/ijmm.2017.3087
10.1189/jlb.0106041
10.3892/mmr.2014.2606
10.3892/ijo.2017.4083
10.3389/fimmu.2017.00403
10.3109/08830189909088495
10.3390/vaccines3020344
10.1007/s00262-010-0816-2
10.1034/j.1600-065X.2002.18809.x
10.1177/1933719110396230
10.1016/j.ejcb.2010.10.006
10.1002/eji.201646837
10.2174/092986708784872384
10.3389/fimmu.2016.00382
10.1007/978-0-387-89520-8_5
10.1101/cshperspect.a006080
10.1128/CVI.00010-17
10.1615/CritRevImmunol.2014009988
10.1186/s13054-017-1807-x
10.1038/cti.2017.28
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright Elsevier BV Feb 2018
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
– notice: Copyright Elsevier BV Feb 2018
DBID NPM
AAYXX
CITATION
7QO
7T5
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
DOI 10.1016/j.intimp.2017.12.029
DatabaseName PubMed
CrossRef
Biotechnology Research Abstracts
Immunology Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1878-1705
EndPage 311
ExternalDocumentID 10_1016_j_intimp_2017_12_029
29310106
S1567576917305027
Genre Journal Article
GroupedDBID ---
--K
--M
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29J
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATCM
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACIWK
ACPRK
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFRAH
AFTJW
AFXIZ
AGEKW
AGHFR
AGUBO
AGYEJ
AI.
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
C45
CJTIS
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
L7B
LCYCR
LUGTX
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSI
SSP
SSZ
T5K
TEORI
UNMZH
VH1
ZGI
~G-
AAXKI
AKRWK
NPM
AAYXX
AFJKZ
CITATION
7QO
7T5
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c339t-d24a1fbc3ce7e1c1ff031228483f078a0ef063820f30b5d5ea58375252ac0d533
IEDL.DBID AIKHN
ISSN 1567-5769
IngestDate Fri Aug 16 20:40:45 EDT 2024
Thu Oct 10 22:15:24 EDT 2024
Thu Sep 26 20:08:23 EDT 2024
Wed Oct 16 00:58:53 EDT 2024
Fri Feb 23 02:45:46 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords Tumor cell lysate
FasL
Mouse splenocytes
Lung cancer
Apoptosis
Anti-tumor immunity
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c339t-d24a1fbc3ce7e1c1ff031228483f078a0ef063820f30b5d5ea58375252ac0d533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 29310106
PQID 2066666910
PQPubID 2045469
PageCount 6
ParticipantIDs proquest_miscellaneous_1989557642
proquest_journals_2066666910
crossref_primary_10_1016_j_intimp_2017_12_029
pubmed_primary_29310106
elsevier_sciencedirect_doi_10_1016_j_intimp_2017_12_029
PublicationCentury 2000
PublicationDate 2018-02-01
PublicationDateYYYYMMDD 2018-02-01
PublicationDate_xml – month: 02
  year: 2018
  text: 2018-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Amsterdam
PublicationTitle International immunopharmacology
PublicationTitleAlternate Int Immunopharmacol
PublicationYear 2018
Publisher Elsevier B.V
Elsevier BV
Publisher_xml – name: Elsevier B.V
– name: Elsevier BV
References Rehg, Sundberg (bb0050) 2008; 58
Guo, Xu, Ge, Zhang, Zheng, Xu, Liu, Li, Ge (bb0120) 2017 Oct; 40
Yamada, Arakaki, Saito, Kudo, Ishimaru (bb0030) 2017; 8
Lettau, Paulsen, Schmidt, Janssen (bb0090) 2011; 90
Ehrenschwender, Wajant (bb0015) 2009; 647
Volpe, Sambucci, Battistini, Borsellino (bb0020) 2016; 7
Li, Xu, Jiang, Zhao, Ge, Zheng (bb0055) 2015; 8
Chiang, Coukos, Kandalaft (bb0065) 2015; 3
Jordan, Gupta, Ogendi, Bakshi, Kapil, Press, Sabbaj, Lee, Geisler (bb0125) 2017; 24
Dong, Dai, Xu, Zhang, Ling, Sun, Lv (bb0010) 2014; 10
Li, Yu, Sun, Wang, Zhang, Wei, Wang, Wan, Cao, Wang, Chen, Dong, Wang (bb0005) 2010; 25
Rivoltini, Carrabba, Huber, Castelli, Novellino, Dalerba, Mortarini, Arancia, Anichini, Fais, Parmiani (bb0060) 2002; 188
Grant, Shields, Neumann, Kramer, Bonato, Jackson, Baird, Young (bb0070) 2017; 6
Lettau, Paulsen, Kabelitz, Janssen (bb0085) 2008; 15
Szarynska, Olejniczak, Wierzbicki, Kobiela, Laski, Sledzinski, Adrych, Guzek, Kmiec (bb0035) 2017; 51
Barragán, de Frias, Iglesias-Serret, Campàs, Castaño, Santidrián, Coll-Mulet, Cosialls, Domingo, Pons, Gil (bb0115) 2006; 80
Cibrián, Sánchez-Madrid (bb0100) 2017; 47
Bhatraju, Robinson-Cohen, Mikacenic, Harju-Baker, Dmyterko, Slivinski, Liles, Himmelfarb, Heckbert, Wurfel, Mishra, Panda, Sahoo, Bal, Satapathy (bb0025) 2017; 21
Zhao, Jia, Cheng, Xiao, Li, Ren, Li, Feng, Feng, Wang, Zheng (bb0075) 2017; 37
Chen, Yen, Lin, Lee, Soong, Lai, Lin (bb0080) 2011; 18
Markov, Mironova, Vlasov, Zenkova (bb0135) 2016; 8
Arakaki, Yamada, Kudo, Hayashi, Ishimaru (bb0040) 2014; 34
Ju, Matsui, Ozdemirli (bb0045) 1999; 18
Gollmer, Asperti-Boursin, Tanaka (bb0110) 2009; 114
Green, Llambi (bb0095) 2015; 7
Dong, Sun, Wu, Zhang, Wang, Wei, Zhou, Hu, Yu, Hua, Wang (bb0130) 2010; 59
Levin, Zhang, Kadlecek (bb0105) 2008; 283
Bhatraju (10.1016/j.intimp.2017.12.029_bb0025) 2017; 21
Rehg (10.1016/j.intimp.2017.12.029_bb0050) 2008; 58
Yamada (10.1016/j.intimp.2017.12.029_bb0030) 2017; 8
Zhao (10.1016/j.intimp.2017.12.029_bb0075) 2017; 37
Szarynska (10.1016/j.intimp.2017.12.029_bb0035) 2017; 51
Jordan (10.1016/j.intimp.2017.12.029_bb0125) 2017; 24
Arakaki (10.1016/j.intimp.2017.12.029_bb0040) 2014; 34
Volpe (10.1016/j.intimp.2017.12.029_bb0020) 2016; 7
Chiang (10.1016/j.intimp.2017.12.029_bb0065) 2015; 3
Barragán (10.1016/j.intimp.2017.12.029_bb0115) 2006; 80
Guo (10.1016/j.intimp.2017.12.029_bb0120) 2017; 40
Ju (10.1016/j.intimp.2017.12.029_bb0045) 1999; 18
Green (10.1016/j.intimp.2017.12.029_bb0095) 2015; 7
Gollmer (10.1016/j.intimp.2017.12.029_bb0110) 2009; 114
Markov (10.1016/j.intimp.2017.12.029_bb0135) 2016; 8
Levin (10.1016/j.intimp.2017.12.029_bb0105) 2008; 283
Ehrenschwender (10.1016/j.intimp.2017.12.029_bb0015) 2009; 647
Dong (10.1016/j.intimp.2017.12.029_bb0130) 2010; 59
Chen (10.1016/j.intimp.2017.12.029_bb0080) 2011; 18
Li (10.1016/j.intimp.2017.12.029_bb0005) 2010; 25
Lettau (10.1016/j.intimp.2017.12.029_bb0090) 2011; 90
Cibrián (10.1016/j.intimp.2017.12.029_bb0100) 2017; 47
Li (10.1016/j.intimp.2017.12.029_bb0055) 2015; 8
Rivoltini (10.1016/j.intimp.2017.12.029_bb0060) 2002; 188
Dong (10.1016/j.intimp.2017.12.029_bb0010) 2014; 10
Grant (10.1016/j.intimp.2017.12.029_bb0070) 2017; 6
Lettau (10.1016/j.intimp.2017.12.029_bb0085) 2008; 15
References_xml – volume: 8
  start-page: 403
  year: 2017
  ident: bb0030
  article-title: Dual role of Fas/FasL-mediated signal in peripheral immune tolerance
  publication-title: Front. Immunol.
  contributor:
    fullname: Ishimaru
– volume: 80
  start-page: 1473
  year: 2006
  end-page: 1479
  ident: bb0115
  article-title: Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}
  publication-title: J. Leukoc. Biol.
  contributor:
    fullname: Gil
– volume: 10
  start-page: 2827
  year: 2014
  end-page: 2834
  ident: bb0010
  article-title: Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes
  publication-title: Mol. Med. Rep.
  contributor:
    fullname: Lv
– volume: 58
  start-page: 246
  year: 2008
  end-page: 252
  ident: bb0050
  article-title: Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice
  publication-title: Comp. Med.
  contributor:
    fullname: Sundberg
– volume: 8
  start-page: 17
  year: 2016
  end-page: 30
  ident: bb0135
  article-title: Molecular and cellular mechanisms of antitumor immune response activation by dendritic cells
  publication-title: Acta Nat.
  contributor:
    fullname: Zenkova
– volume: 647
  start-page: 64
  year: 2009
  end-page: 93
  ident: bb0015
  article-title: The role of FasL and Fas in health and disease
  publication-title: Adv. Exp. Med. Biol.
  contributor:
    fullname: Wajant
– volume: 47
  start-page: 946
  year: 2017
  end-page: 953
  ident: bb0100
  article-title: CD69: from activation marker to metabolic gatekeeper
  publication-title: Eur. J. Immunol.
  contributor:
    fullname: Sánchez-Madrid
– volume: 25
  start-page: 185
  year: 2010
  end-page: 191
  ident: bb0005
  article-title: Vaccination with B16 tumor cell lysate plus recombinant Mycobacterium tuberculosis Hsp70 induces antimelanoma effect in mice
  publication-title: Cancer Biother. Radiopharm.
  contributor:
    fullname: Wang
– volume: 3
  start-page: 344
  year: 2015
  end-page: 372
  ident: bb0065
  article-title: Whole tumor antigen vaccines: where are we?
  publication-title: Vaccines (Basel)
  contributor:
    fullname: Kandalaft
– volume: 24
  year: 2017
  ident: bb0125
  article-title: The predominant CD4
  publication-title: Clin. Vaccine Immunol.
  contributor:
    fullname: Geisler
– volume: 8
  start-page: 11915
  year: 2015
  end-page: 11920
  ident: bb0055
  article-title: Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues
  publication-title: Int. J. Clin. Exp. Pathol.
  contributor:
    fullname: Zheng
– volume: 21
  start-page: 217
  year: 2017
  ident: bb0025
  article-title: Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype
  publication-title: Crit. Care
  contributor:
    fullname: Satapathy
– volume: 15
  start-page: 1684
  year: 2008
  end-page: 1696
  ident: bb0085
  article-title: Storage, expression and function of Fas ligand, the key death factor of immune cells
  publication-title: Curr. Med. Chem.
  contributor:
    fullname: Janssen
– volume: 7
  start-page: 382
  year: 2016
  ident: bb0020
  article-title: Fas-Fas ligand: checkpoint of T cell functions in multiple sclerosis
  publication-title: Front. Immunol.
  contributor:
    fullname: Borsellino
– volume: 51
  start-page: 975
  year: 2017
  end-page: 986
  ident: bb0035
  article-title: FasR and FasL in colorectal cancer
  publication-title: Int. J. Oncol.
  contributor:
    fullname: Kmiec
– volume: 37
  start-page: 3405
  year: 2017
  end-page: 3414
  ident: bb0075
  article-title: Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma
  publication-title: Oncol. Rep.
  contributor:
    fullname: Zheng
– volume: 59
  start-page: 899
  year: 2010
  end-page: 908
  ident: bb0130
  article-title: Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice
  publication-title: Cancer Immunol. Immunother.
  contributor:
    fullname: Wang
– volume: 6
  start-page: e149
  year: 2017
  ident: bb0070
  article-title: Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8
  publication-title: Clin. Transl. Immunol.
  contributor:
    fullname: Young
– volume: 90
  start-page: 456
  year: 2011
  end-page: 466
  ident: bb0090
  article-title: Insights into the molecular regulation of FasL (CD178) biology
  publication-title: Eur. J. Cell Biol.
  contributor:
    fullname: Janssen
– volume: 283
  start-page: 15419
  year: 2008
  end-page: 15430
  ident: bb0105
  article-title: Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling
  publication-title: J. Biol. Chem.
  contributor:
    fullname: Kadlecek
– volume: 18
  start-page: 485
  year: 1999
  end-page: 513
  ident: bb0045
  article-title: Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction
  publication-title: Int. Rev. Immunol.
  contributor:
    fullname: Ozdemirli
– volume: 188
  start-page: 97
  year: 2002
  end-page: 113
  ident: bb0060
  article-title: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
  publication-title: Immunol. Rev.
  contributor:
    fullname: Parmiani
– volume: 7
  year: 2015
  ident: bb0095
  article-title: Cell death signaling
  publication-title: Cold Spring Harb. Perspect. Biol.
  contributor:
    fullname: Llambi
– volume: 114
  start-page: 580
  year: 2009
  end-page: 588
  ident: bb0110
  article-title: CCL21 mediates CD4 + T - cell costimulation via a DOCK2/Rac-dependent pathway
  publication-title: Blood
  contributor:
    fullname: Tanaka
– volume: 40
  start-page: 979
  year: 2017 Oct
  end-page: 986
  ident: bb0120
  article-title: Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells
  publication-title: Int. J. Mol. Med.
  contributor:
    fullname: Ge
– volume: 18
  start-page: 687
  year: 2011
  end-page: 694
  ident: bb0080
  article-title: Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects
  publication-title: Reprod. Sci.
  contributor:
    fullname: Lin
– volume: 34
  start-page: 301
  year: 2014
  end-page: 314
  ident: bb0040
  article-title: Mechanism of activation-induced cell death of T cells and regulation of FasL expression
  publication-title: Crit. Rev. Immunol.
  contributor:
    fullname: Ishimaru
– volume: 37
  start-page: 3405
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0075
  article-title: Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2017.5629
  contributor:
    fullname: Zhao
– volume: 283
  start-page: 15419
  year: 2008
  ident: 10.1016/j.intimp.2017.12.029_bb0105
  article-title: Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M709000200
  contributor:
    fullname: Levin
– volume: 114
  start-page: 580
  year: 2009
  ident: 10.1016/j.intimp.2017.12.029_bb0110
  article-title: CCL21 mediates CD4 + T - cell costimulation via a DOCK2/Rac-dependent pathway
  publication-title: Blood
  doi: 10.1182/blood-2009-01-200923
  contributor:
    fullname: Gollmer
– volume: 8
  start-page: 17
  year: 2016
  ident: 10.1016/j.intimp.2017.12.029_bb0135
  article-title: Molecular and cellular mechanisms of antitumor immune response activation by dendritic cells
  publication-title: Acta Nat.
  doi: 10.32607/20758251-2016-8-3-17-30
  contributor:
    fullname: Markov
– volume: 25
  start-page: 185
  year: 2010
  ident: 10.1016/j.intimp.2017.12.029_bb0005
  article-title: Vaccination with B16 tumor cell lysate plus recombinant Mycobacterium tuberculosis Hsp70 induces antimelanoma effect in mice
  publication-title: Cancer Biother. Radiopharm.
  doi: 10.1089/cbr.2009.0716
  contributor:
    fullname: Li
– volume: 40
  start-page: 979
  issue: 4
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0120
  article-title: Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells
  publication-title: Int. J. Mol. Med.
  doi: 10.3892/ijmm.2017.3087
  contributor:
    fullname: Guo
– volume: 80
  start-page: 1473
  year: 2006
  ident: 10.1016/j.intimp.2017.12.029_bb0115
  article-title: Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.0106041
  contributor:
    fullname: Barragán
– volume: 10
  start-page: 2827
  year: 2014
  ident: 10.1016/j.intimp.2017.12.029_bb0010
  article-title: Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2014.2606
  contributor:
    fullname: Dong
– volume: 8
  start-page: 11915
  year: 2015
  ident: 10.1016/j.intimp.2017.12.029_bb0055
  article-title: Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues
  publication-title: Int. J. Clin. Exp. Pathol.
  contributor:
    fullname: Li
– volume: 51
  start-page: 975
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0035
  article-title: FasR and FasL in colorectal cancer
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2017.4083
  contributor:
    fullname: Szarynska
– volume: 8
  start-page: 403
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0030
  article-title: Dual role of Fas/FasL-mediated signal in peripheral immune tolerance
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00403
  contributor:
    fullname: Yamada
– volume: 18
  start-page: 485
  issue: 5–6
  year: 1999
  ident: 10.1016/j.intimp.2017.12.029_bb0045
  article-title: Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction
  publication-title: Int. Rev. Immunol.
  doi: 10.3109/08830189909088495
  contributor:
    fullname: Ju
– volume: 3
  start-page: 344
  year: 2015
  ident: 10.1016/j.intimp.2017.12.029_bb0065
  article-title: Whole tumor antigen vaccines: where are we?
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines3020344
  contributor:
    fullname: Chiang
– volume: 59
  start-page: 899
  year: 2010
  ident: 10.1016/j.intimp.2017.12.029_bb0130
  article-title: Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-010-0816-2
  contributor:
    fullname: Dong
– volume: 188
  start-page: 97
  year: 2002
  ident: 10.1016/j.intimp.2017.12.029_bb0060
  article-title: Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction
  publication-title: Immunol. Rev.
  doi: 10.1034/j.1600-065X.2002.18809.x
  contributor:
    fullname: Rivoltini
– volume: 18
  start-page: 687
  year: 2011
  ident: 10.1016/j.intimp.2017.12.029_bb0080
  article-title: Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects
  publication-title: Reprod. Sci.
  doi: 10.1177/1933719110396230
  contributor:
    fullname: Chen
– volume: 90
  start-page: 456
  year: 2011
  ident: 10.1016/j.intimp.2017.12.029_bb0090
  article-title: Insights into the molecular regulation of FasL (CD178) biology
  publication-title: Eur. J. Cell Biol.
  doi: 10.1016/j.ejcb.2010.10.006
  contributor:
    fullname: Lettau
– volume: 47
  start-page: 946
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0100
  article-title: CD69: from activation marker to metabolic gatekeeper
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201646837
  contributor:
    fullname: Cibrián
– volume: 15
  start-page: 1684
  year: 2008
  ident: 10.1016/j.intimp.2017.12.029_bb0085
  article-title: Storage, expression and function of Fas ligand, the key death factor of immune cells
  publication-title: Curr. Med. Chem.
  doi: 10.2174/092986708784872384
  contributor:
    fullname: Lettau
– volume: 7
  start-page: 382
  year: 2016
  ident: 10.1016/j.intimp.2017.12.029_bb0020
  article-title: Fas-Fas ligand: checkpoint of T cell functions in multiple sclerosis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2016.00382
  contributor:
    fullname: Volpe
– volume: 647
  start-page: 64
  year: 2009
  ident: 10.1016/j.intimp.2017.12.029_bb0015
  article-title: The role of FasL and Fas in health and disease
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-0-387-89520-8_5
  contributor:
    fullname: Ehrenschwender
– volume: 7
  year: 2015
  ident: 10.1016/j.intimp.2017.12.029_bb0095
  article-title: Cell death signaling
  publication-title: Cold Spring Harb. Perspect. Biol.
  doi: 10.1101/cshperspect.a006080
  contributor:
    fullname: Green
– volume: 58
  start-page: 246
  year: 2008
  ident: 10.1016/j.intimp.2017.12.029_bb0050
  article-title: Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice
  publication-title: Comp. Med.
  contributor:
    fullname: Rehg
– volume: 24
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0125
  article-title: The predominant CD4+ Th1 cytokine elicited to chlamydia trachomatis infection in women IsTumor necrosis factor alpha and not interferon gamma
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00010-17
  contributor:
    fullname: Jordan
– volume: 34
  start-page: 301
  year: 2014
  ident: 10.1016/j.intimp.2017.12.029_bb0040
  article-title: Mechanism of activation-induced cell death of T cells and regulation of FasL expression
  publication-title: Crit. Rev. Immunol.
  doi: 10.1615/CritRevImmunol.2014009988
  contributor:
    fullname: Arakaki
– volume: 21
  start-page: 217
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0025
  article-title: Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype
  publication-title: Crit. Care
  doi: 10.1186/s13054-017-1807-x
  contributor:
    fullname: Bhatraju
– volume: 6
  start-page: e149
  year: 2017
  ident: 10.1016/j.intimp.2017.12.029_bb0070
  article-title: Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ Tcells
  publication-title: Clin. Transl. Immunol.
  doi: 10.1038/cti.2017.28
  contributor:
    fullname: Grant
SSID ssj0017041
Score 2.2463076
Snippet In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 306
SubjectTerms Anti-tumor immunity
Antigens
Apoptosis
Cancer
Cancer vaccines
FasL
FasL protein
Immunity
Immunity (Disease)
Immunization
Interleukin 2
Lung cancer
Lung carcinoma
Mice
Mouse splenocytes
Splenocytes
Tumor cell lysate
Tumors
Vaccines
Title Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice
URI https://dx.doi.org/10.1016/j.intimp.2017.12.029
https://www.ncbi.nlm.nih.gov/pubmed/29310106
https://www.proquest.com/docview/2066666910
https://search.proquest.com/docview/1989557642
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB90RfDl8Nv1ixyIT8Zt2qbNPsrisnoqC66iTyFNU6h4dbHdh33xb3fStCvCHQfXtzYNhPwmM7-ZTCYAJ_00NEbHnKqwryjaY48mwtOUiUxkqaj3lmy2xV00egivn_jTEgzaszA2rbLR_U6n19q6-dJrZrM3zfPePXoeMbJl9DdQZtG7WoYVNEdh2IGVi6tfo7vFZkLsha5sKuoE26E9QVeneeVFlf-2hStZXMcFa675Rwv1NwZaW6LhOvxoKCS5cKPcgCVTbMKqu1RyvgmnY1eNen5GJl-Hq8ozckrGX3Wq51vw_Ki0zl00kNh4LBmq8ob2JoMbMn2dleR2dD-OOEGvHfEvSV7HH0xKEIycvqKWINrKzDu22EMm1Rx_JfZ6-214GF5OBiPa3LRAdRD0K5r6oWJZogNtYsM0yzJc6z5aLhFkyCGUZzJLbXwvC7yEp9wojo4t97mvtJciY9yBTvFWmD0giWamL-LERLaynvGFDiLFlYgSo5Bs8S7Qdnbl1BXUkG2m2Yt0aEiLhmS-RDS6ELcQyG-CIVHn_6PnYYuYbBZmKW31enyQJHXh56IZl5TdJ1GFeZuV0qaRcRSU0O_CrkN6MVRkR8y60fv_PawDWMM34TK_D6FTvc_MERKbKjmG5fMPdtyI7yc9ePXL
link.rule.ids 315,786,790,4521,24144,27955,27956,45618,45712
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ra9swED66jrG9jK1ru2xdp8HoU9VYtmUrjyMsZFtaAk1H9yRkWQaX1g2185CX_fbdWXbKoGNQP1oyCH-nu-9OdyeAz6M8ds6mkpt4ZDja44BnKrBcqEIVuWrPlijb4iyZXsTfL-XlFoz7WhhKq-x0v9fprbbu3gy7vzlcluXwHD2PFNky-hsos-hdPYGnxAYor-vk9ybPQ6RB7Jumokag6X39XJvkVVZNeUNtK0XaRgVbpvmgffoX_2zt0OQVvOwIJPvi1_gatly1A8_8lZLrHTia-17U62O2uC-tqo_ZEZvfd6lev4FfP421pY8FMorGsompZ3y4GM_Y8npVs9Pp-TyRDH12RL9mZRt9cDlDKEp-jTqCWZKYOxyhEpNmjVMZXW6_CxeTr4vxlHf3LHAbRaOG52FsRJHZyLrUCSuKAnd6iHZLRQUyCBO4gohNGBRRkMlcOiPRrZWhDI0NcuSLe7Bd3VbuLbDMCjdSaeYS6qvnQmWjxEijkswZpFpyALz_u3rp22noPs_sSns0NKGhRagRjQGkPQT6L7HQqPH_8-VBj5jutmWtqXc9PkiRBvBpM4wbik5JTOVuV7WmJDKJghKHA9j3SG-WitxIkBP97tHL-gjPp4vTmZ59O_vxHl7giPI54Aew3dyt3AekOE122IrwH2r19qA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccination+with+FasL-%2FTCL+plus+MHSP65+induces+improved+anti-lung+cancer+immunity+in+mice&rft.jtitle=International+immunopharmacology&rft.au=Dong%2C+Bohan&rft.au=Dai%2C+Guangli&rft.au=Ding%2C+Yuanyuan&rft.au=Wang%2C+Beiru&rft.date=2018-02-01&rft.eissn=1878-1705&rft.volume=55&rft.spage=306&rft_id=info:doi/10.1016%2Fj.intimp.2017.12.029&rft_id=info%3Apmid%2F29310106&rft.externalDocID=29310106
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1567-5769&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1567-5769&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1567-5769&client=summon